BA
CTIC

BlackRock Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

BlackRock Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$11K Hold
2,641
– – ﹤0.01% 3563
2016
Q3 		$10K Hold
2,641
– – ﹤0.01% 3582
2016
Q2 		$9K Sell
2,641
-6,588
-71% -$30.2K ﹤0.01% 3608
2016
Q1 		$49K Buy
9,229
+476
+5% +$3.8K ﹤0.01% 3169
2015
Q4 		$108K Sell
8,753
-1,946
-18% -$26K ﹤0.01% 2890
2015
Q3 		$156K Sell
10,699
-471
-4% -$8.14K ﹤0.01% 2865
2015
Q2 		$218K Buy
11,170
+1,114
+11% +$21.5K ﹤0.01% 2748
2015
Q1 		$182K Buy
10,056
+1,253
+14% +$28.2K ﹤0.01% 2737
2014
Q4 		$208K Buy
8,803
+187
+2% +$4.32K ﹤0.01% 2599
2014
Q3 		$209K Sell
8,616
-114
-1% -$2.96K ﹤0.01% 2586
2014
Q2 		$245K Sell
8,730
-733
-8% -$22K ﹤0.01% 2515
2014
Q1 		$322K Sell
9,463
-68,593
-88% -$2.34M ﹤0.01% 2365
2013
Q4 		$1.49M Buy
78,056
+772
+1% +$14.1K ﹤0.01% 1291
2013
Q3 		$1.25M Buy
77,284
+821
+1% +$9.51K ﹤0.01% 1321
2013
Q2 		$803K Buy
+76,463
New +$896K ﹤0.01% 1496

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

BlackRock Advisors's CTIC Position: Q4 2016 in Review

BlackRock Advisors held its CTI BioPharma Corp. (DE) Common Stock (CTIC) position steady in Q4 2016 at 2,641 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #3563.

BlackRock Advisors first reported a position in CTIC in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.49M in Q4 2013. 58 funds tracked by Wall St. Rank hold CTIC as of Q4 2016.

  • BlackRock Advisors held 2,641 shares of CTI BioPharma Corp. (DE) Common Stock worth $11K as of Q4 2016.
  • BlackRock Advisors left its CTI BioPharma Corp. (DE) Common Stock share count unchanged in Q4 2016.
  • CTI BioPharma Corp. (DE) Common Stock made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3563 holding.
  • BlackRock Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $1.49M in Q4 2013.
  • 58 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.